In the pharmaceutical industry, quality has always been a regulatory requirement. However, in recent years, the conversation has shifted from simply meeting Good Manufacturing Practice (GMP) requirements to building a proactive quality culture embedded across the entire organisation. By 2025, many pharmaceutical leaders recognised that strong systems alone are not enough. Regulators, including the
In 2026, supply chains are more globalised, interconnected, and complex than ever before. Organisations increasingly rely on international suppliers to deliver raw materials, components, and services essential to their operations. While global sourcing provides cost advantages and access to specialised capabilities, it also introduces significant quality and compliance challenges. Supplier quality management has therefore
Remote auditing was once considered a temporary workaround and an emergency solution to maintain compliance during global disruption. But in 2026, it has cemented itself as a core component of modern quality oversight. The pharmaceutical and medical device industries, along with global regulatory authorities, have embraced hybrid audit models that blend on-site inspections with
Risk-based quality management has been a core expectation in pharmaceutical manufacturing ever since ICH Q9 introduced the concept of integrating science and risk into quality decision-making. However, in 2026, the role of risk-based thinking is undergoing a significant transformation. As digitalisation accelerates and manufacturing processes become more complex, organisations increasingly rely on smart tools,
